Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Chen, Gang; Huang, Alexander C; Zhang, Wei; Zhang, Gao; Wu, Min; Xu, Wei; Yu, Zili; Yang, Jiegang; Wang, Beike; Sun, Honghong; Xia, Houfu; Man, Qiwen; Zhong, Wenqun; Antelo, Leonardo F; Wu, Bin; Xiong, Xuepeng; Liu, Xiaoming; Guan, Lei; Li, Ting; Liu, Shujing; Yang, Ruifeng; Lu, Youtao; Dong, Liyun; McGettigan, Suzanne; Somasundaram, Rajasekharan; Radhakrishnan, Ravi; Mills, Gordon; Lu, Yiling; Kim, Junhyong; Chen, Youhai H; Dong, Haidong; Zhao, Yifang; Karakousis, Giorgos C; Mitchell, Tara C; Schuchter, Lynn M; Herlyn, Meenhard; Wherry, E John; Xu, Xiaowei; Guo, Wei.
; 560(7718): 382-386, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30089911
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
Mechanisms Controlling PD-L1 Expression in Cancer.
Coinhibitory Pathways in Immunotherapy for Cancer.
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
Regulatory mechanisms of PD-L1 expression in cancer cells.
Round optimization for improved discovery of native bispecific antibodies.
ERADicate Tumor Progression with Metformin.
Dimers Aren't Forever: CD80 Breaks up with PD-L1.
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.